Colorectal cancer is the most common gastrointestinal malignancy and the third most frequently diagnosed cancer worldwide. Trifluridine/tipiracil represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for currently available therapies. We present a case of a young woman with refractory metastatic colorectal cancer treated with this agent as the IV line of chemotherapy in which remarkable prolongation of progression free survival time was observed.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.